|
WO2021001538A1
|
|
Novel galactoside inhibitor of galectins
|
|
WO2021004940A1
|
|
Novel galactoside inhibitor of galectins
|
|
WO2021001528A1
|
|
Novel galactoside inhibitor of galectins
|
|
WO2020260351A1
|
|
Large scale process of 3,3'-dideoxy-3,3'-bis-[4-(3-fluorophenyl)-1h-1,2,3-triazol-1-yl]-1,1'-sulfanediyl-di-beta-d-galactopyranoside
|
|
WO2020127461A1
|
|
Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside
|
|
WO2020104335A1
|
|
Alpha-d-galactoside inhibitors of galectins
|
|
CA3113956A1
|
|
Galactoside inhibitor of galectins
|
|
CA3114055A1
|
|
Prodrug of galactoside inhibitors of galectins
|
|
CA3086092A1
|
|
Novel galactoside inhibitor of galectins
|
|
CA3025866A1
|
|
Alpha-d-galactoside inhibitors of galectins
|
|
WO2018011094A1
|
|
Alpha-d-galactoside inhibitors of galectins
|
|
CN108602847A
|
|
polymorphic and method
|
|
EP3374368A1
|
|
1,1 '-sulfanediyl-di-beta-d-galactopyranosides as inhibitors of galectins
|
|
CA2970062A1
|
|
Alpha-d-galactoside inhibitors of galectins
|
|
EP3245216A1
|
|
Novel galactoside inhibitor of galectins
|
|
CN106536537A
|
|
Novel hybrid galactoside inhibitor of galectins
|
|
JP2016216377A
|
|
Once-daily treatment of pulmonary fibrosis
|
|
WO2016180483A1
|
|
Once-daily treatment of pulmonary fibrosis
|
|
EP3129032A1
|
|
Galactoside inhibitors for the treatment of alpha-synucleinopthies
|
|
CN104755088A
|
|
Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
|
